Skip to content

US · VRCA · BIOTECHNOLOGY

Verrica Pharmaceuticals Inc. (VRCA) intrinsic value and stock valuation

$2.74as of 2026-11-21 · Mkt cap 58.69M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Verrica Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values VRCA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VRCA’s statements →

Verrica Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology West Chester, PA 19380 verrica.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$35.6M
20162025
Net income
-$-17.89M
20162025
Free cash flow
-$-17.63M
20162025
Total equity
$24.7M-5.6% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$35.6M$7.57M$5.12M$9.03M$12M
Operating income-$-11.94M-$-65.92M-$-65.76M-$-21.3M-$-30.91M
Net income-$-17.89M-$-76.58M-$-67M-$-24.49M-$-35.08M
EPSd-$-1.68M-$-14.78M-$-14.79M-$-7.16M-$-12.99M
Operating cash flow-$-17.63M-$-60.93M-$-38.58M-$-18.65M-$-27.58M
Capital expenditure$0.00-$-30K-$-360K-$-300K-$-880K
Free cash flow-$-17.63M-$-60.95M-$-38.94M-$-18.95M-$-28.46M
Total assets$47.1M$54.1M$81.6M$44.7M$80.1M
Total debt$1.63M$45.9M$45.5M$1.53M$43.4M
Net debt-$-28.52M-$-390K-$-24.04M-$-32.75M$27.7M
Total equity$24.7M-$-9.86M$19.8M$40M$32.6M
Cash and short-term investments$30.2M$46.3M$69.6M$34.3M$70.4M
Income statement
20252024202320222021
Revenue$35.6M$7.57M$5.12M$9.03M$12M
Cost of revenue$3.44M$2.74M$750K$720K$470K
Gross profit$32.1M$4.83M$4.38M$8.31M$11.5M
Research and development expenses$8.86M$11.8M$20.3M$12.2M$15.9M
Selling, general and administrative expenses$35.2M$58.8M$47.3M$17.4M$27M
Other expenses$0.00$80K$2.54M$0.00-$-470K
Operating expenses$44.1M$70.8M$70.1M$29.6M$42.4M
Cost and expenses$47.5M$73.5M$70.9M$30.3M$42.9M
Interest income$930K$1.42M$2.74M$480K$120K
Interest expense$7.74M$9.41M$3.96M$2.17M$4.29M
Depreciation and amortization$780K$1.27M$840K$720K$470K
Ebitda-$-9.36M-$-65.9M-$-62.2M-$-21.6M-$-30.31M
Operating income-$-11.94M-$-65.92M-$-65.76M-$-21.3M-$-30.91M
Total other income/expenses, net-$-5.95M-$-10.66M-$-1.24M-$-3.19M-$-4.17M
Income before tax-$-17.89M-$-76.58M-$-67M-$-24.49M-$-35.08M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-17.89M-$-76.58M-$-67M-$-24.49M-$-35.08M
Weighted average shares outstanding$10.7M$5.18M$4.53M$3.42M$2.7M
Weighted average diluted shares outstanding$10.7M$5.18M$4.53M$3.42M$2.7M
Balance sheet
20252024202320222021
Cash and short-term investments$30.2M$46.3M$69.6M$34.3M$70.4M
Net receivables$5.4M$80K$4.42M$490K$0.00
Inventory$2.24M$2.46M$1.02M$0.00$0.00
Total current assets$42.5M$51.2M$77.5M$39.1M$74.3M
Property, plant and equipment, net$1.86M$2.58M$3.62M$5.33M$5.5M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$4.59M$2.96M$4.07M$5.61M$5.8M
Total assets$47.1M$54.1M$81.6M$44.7M$80.1M
Accounts payable$2.07M$1.9M$2.46M$510K$840K
Short-term debt$750K$13.6M$700K$300K$41.9M
Deferred revenue$780K$0.00$0.00$0.00$0.00
Total current liabilities$16.4M$29M$17M$3.46M$46.1M
Long-term debt$890K$32.3M$44.8M$1.23M$1.47M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.95M$35M$44.8M$1.23M$1.47M
Capital lease obligations$1.63M$2.02M$2.64M$1.53M$1.72M
Total liabilities$22.4M$64M$61.8M$4.69M$47.5M
Common stock$0.00$10K$0.00$0.00$0.00
Retained earnings-$-324.91M-$-307.03M-$-230.45M-$-163.45M-$-138.97M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$-30K
Total equity$24.7M-$-9.86M$19.8M$40M$32.6M
Total investments$0.00$0.00$0.00$0.00$54.6M
Total debt$1.63M$45.9M$45.5M$1.53M$43.4M
Net debt-$-28.52M-$-390K-$-24.04M-$-32.75M$27.7M
Cash flow statement
20252024202320222021
Net income-$-17.89M-$-76.58M-$-67M-$-24.49M-$-35.08M
Depreciation and amortization$430K$1.27M$840K$720K$470K
Stock-based compensation$3.32M$7.16M$14.4M$4.99M$6.05M
Change in working capital-$-6.25M$2.03M$9.86M-$-1.8M-$-540K
Accounts receivable-$-5.32M$4.34M-$-3.93M-$-490K$0.00
Inventory$0.00$0.00$0.00$490K$0.00
Accounts payable$180K-$-570K$2.2M-$-340K$500K
Net cash provided by operating activities-$-17.63M-$-60.93M-$-38.58M-$-18.65M-$-27.58M
Investments in property, plant and equipment$0.00-$-30K-$-360K-$-300K-$-880K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-20K-$-360K$54M-$-1M
Common stock issued$50.1M$39.6M$30.3M$26.9M$28.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.45M$37.7M$74.2M-$-16.87M$33.7M
Net change in cash-$-16.18M-$-23.22M$35.3M$18.5M$5.07M
Cash at end of period$30.2M$46.3M$69.6M$34.3M$15.8M
Operating cash flow-$-17.63M-$-60.93M-$-38.58M-$-18.65M-$-27.58M
Capital expenditure$0.00-$-30K-$-360K-$-300K-$-880K
Free cash flow-$-17.63M-$-60.95M-$-38.94M-$-18.95M-$-28.46M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Verrica Pharmaceuticals Inc.

        Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

        CEO
        Jayson Rieger
        Employees
        76
        Beta
        1.48

        Explore

        Frequently asked questions

        What is the intrinsic value of Verrica Pharmaceuticals Inc. (VRCA)?

        InvestorsCraft does not currently publish an intrinsic value for VRCA. How the IC value is calculated.

        Is VRCA undervalued?

        InvestorsCraft does not publish an undervaluation signal for VRCA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.